Table 2.

Pharmacokinetic parameters of Cur in different carriers after i.p. administration.

Formulations	tmax (h)	Cmax (μg/mL)	MRTlast (h)	MRTINF_obs (h)	AUClast (μg/mL*h)	AUCINF_obs (μg/mL*h)	Vz_F_obs (L/kg)	Cl_F_obs (L/h/kg)
Free-Cur	1	11.520 ± 2.005	2.472 ± 0.316	2.574 ± 0.380	12.344 ± 2.024	12.376 ± 2.040	8.644 ± 2.698	1.244 ± 0.238
Cur-NLCs	2	7.779 ± 1.103*	8.289 ± 0.707*	8.312 ± 0.708*	36.968 ± 4.934*,§	36.986 ± 4.932*,§	2.293 ± 0.634*	0.411 ± 0.052*
Cur-mNLCs	2	6.618 ± 0.835*	9.151 ± 0.928*	9.177 ± 0.932*	48.604 ± 7.948*	48.631 ± 7.944*	1.913 ± 0.452*	0.315 ± 0.051*
Free-Cur vs. Cur-NLCs		<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01
Free-Cur vs. Cur-mNLCs		<0.01	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01
Cur-NLCs vs. Cur-mNLCs		0.173	0.049	0.052	0.002	0.002	0.691	0.266

Data were presented as mean ± SD (n = 6). t _max: the time to achieve the maximum concentration; C _max: the maximum concentration in serum; MRT_last: the mean residence time to last sampling time; MRT_{INF_obs}: the mean residence time to infinity; AUC_last: the concentration-time curve to the last sampling time; AUC_{INF_obs}: the concentration-time curve to infinity; V_{z_F_obs}: apparent volume of distribution; Cl_{_F_obs}: plasma clearance.

*p < .01, compared with Free-Cur; #p < .05, compared with Cur-mNLCs; §p < .01, compared with Cur-mNLCs.